The use of bevacizumab and trastuzumab beyond tumor progression: A new avenue in cancer treatment?

Reviews on Recent Clinical Trials

Volumn 4, Issue 3, 2009, Pages 163-167

  Meriggi, F ^a   Abeni, C ^a   Di Biasi, B ^a   Zaniboni, A ^a  

^a Fondazione Poliambulanza   (Italy)

Author keywords

Bevacizumab; Breast cancer; Colon cancer; Trastuzumab; Use beyond progression

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; IRINOTECAN; LAPATINIB; OXALIPLATIN; TRASTUZUMAB;

ACNE; ASTHENIA; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIARRHEA; DRUG FEVER; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; SURVIVAL ANALYSIS;

EID: 73349119417     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488709789957682     Document Type: Review

References (35)

1. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992; 89: 5321-5.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
5. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
6. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
7. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-70.
8. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25: 3853-8.
9. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5: 52-8.
10. Jackisch C. Her-2 positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 2006; 11(Suppl 1); 34-41.
11. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A Randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc Am Soc Clin Oncol 2008; 26: 15S.
12. Schaller G, Fuchs I, Gonsch T, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007; 25: 3246-50.
13. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:1759-68.
14. Reichardt P, von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14: 1227-33.
15. Gunter von Minckwitz, Andreas du Bois, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 2009; 27: 1999-2006.
16. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 50: 2335-42.
18. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-12.
19. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-44.
20. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE Study. J Clin Oncol 2006; 24: 148S.
21. Khorana A. Bevacizumab beyond progression? Here come (some) data. Medscape 2008.
22. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational Cohort Study (BRiTE). J Clin Oncol 2008; 26: 5326-34.
23. Kopetz S, Abbruzzese JL. Hidden biases in an observational study of bevacizumab beyond progression. J Clin Oncol 2009; 29: 1732.
24. Ellis LM, Haller DG. Bevacizumab beyond progression: does this make sense? J Clin Oncol 2008; 26: 5313-5.
25. Levine MN, Julian JA. Registries that show efficacy: good, but not good enough. J Clin Oncol 2008; 26: 5316.
26. Mulcahym N. Bevacizumab after progression in metastaic colon cancer: beneficial? Medscape 2008.
27. Jahanzeb M. Continuing trastuzumab beyond progression. J Clin Oncol 2009; 27: 1935.
28. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5: 52-8; discussion 59-62.
29. Jackisch C, Eustermann H, Schoenegg W, et al. Clinical use of trastuzumab (Herceptin) in metastatic breast cancer (MBC) in Germany from 2001 to 2006. Presented at San Antonio Breast Cancer Symposium, San Antonio, TX, 2007.
30. Garcia-Saenz JA, Martin M, Puente J, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005; 6: 325-9.
31. Stemmler HJ, Kahlert S, Siekiera W, et al. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005; 28: 5826.
32. Krop IE, Burris HA, Rugo H, et al. Quantitative assessment of HER2 status and correlation with efficacy for patients with metastatic breast cancer in a phase II study of trastuzumab-DM1. J Clin Oncol 2009; 27: 15S.
33. Bedard PL, Piccart-Gebhart MJ. Current paradigms for the use of HER-2 Target therapy in early-stage breast cancer. Clin Breast Cancer 2008; 8(Suppl 4): S157-65.
34. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2009; 112: 533-43.
35. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short- term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 3: 232-9.